Consensus Cogent Biosciences, Inc.

Stocks

COGT

US19240Q2012

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 14:17:15 2026-08-03 EDT			5-day change	1st Jan Change
38.91 ^USD	-0.05%		-3.36%	+10.02%

06-30	Cogent Biosciences Submits New Drug Application for Bezuclastinib in Advanced Systemic Mastocytosis	CI
06-30	Cogent Biosciences Submits US FDA New Drug Application for Potential Mast Cell Disease Treatment	MT

Evolution of the Average Target: Cogent Biosciences, Inc.

Evolution of the Target Price: Cogent Biosciences, Inc.

Changes in Analyst Recommendations: Cogent Biosciences, Inc.

9d9d8e86b.aH8xqx-z7sX3_aVzISTf2HIBCV3h5Gy34mEeIcaxfY4.Kg4JxVrZh5Gmv_EqWUyXry1GZw2-vij6hlEvQrP-N-IMJwSdS4Tbprmbzg~fea574a27f4a6d3ad1d3c3f438b00381

Analysts' recommendations: Cogent Biosciences, Inc.

12-08	Wedbush Adjusts Cogent Biosciences Price Target to $55 From $38, Maintains Outperform Rating	MT
11-11	Wedbush Upgrades Cogent Biosciences to Outperform From Neutral, Raises Price Target to $38 From $13	MT
11-10	Sector Update: Health Care Stocks Advance Late Afternoon	MT
25-10-20	Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib	CI
25-10-16	Stifel Nicolaus Initiates Coverage on Cogent Biosciences With Hold Rating, $16 Price Target	MT
25-09-03	Raymond James Initiates Cogent Biosciences at Strong Buy	MT
25-08-05	Wedbush Ups Price Target on Cogent Biosciences to $13 From $10, Maintains Neutral Rating	MT
25-07-07	Jefferies Adjusts Price Target on Cogent Biosciences to $28 From $23, Maintains Buy Rating	MT
25-05-06	Wedbush Trims Price Target on Cogent Biosciences to $10 From $11, Maintains Neutral Rating	MT
24-12-11	Needham Downgrades Cogent Biosciences to Hold From Buy	MT
24-09-03	Wedbush Adjusts Cogent Biosciences Price Target to $11 From $10, Maintains Neutral Rating	MT
24-02-26	Citigroup Adjusts Price Target on Cogent Biosciences to $13 From $11, Maintains Buy Rating	MT
24-02-26	Baird Downgrades Cogent Biosciences to Neutral From Outperform, Adjusts Price Target to $8 From $14	MT
24-02-23	Wedbush Raises Cogent Biosciences' PT to $10 From $5, Adjusts Peak Penetration Assumptions for Bezuclastinib in Systemic Mastocytosis; Keeps Neutral Rating	MT
24-02-08	Citigroup Initiates Cogent Biosciences at Buy Rating With $11 Price Target	MT
23-12-15	HC Wainwright Adjusts Price Target on Cogent Biosciences to $13 From $27, Keeps Buy Rating	MT
23-12-11	Wedbush Downgrades Cogent Biosciences to Neutral From Outperform, Cuts Price Target to $5 From $20	MT
23-12-08	JPMorgan Chase Starts Coverage on Cogent Biosciences with Overweight Rating, $18 Price Target	MT
23-06-08	HC Wainwright Adjusts Price Target on Cogent Biosciences to $27 From $28, Keeps Buy Rating	MT
23-04-28	Baird Initiates Cogent Biosciences at Outperform With $20 Price Target	MT
23-03-15	Needham Adjusts Price Target on Cogent Biosciences to $23 From $24, Keeps Buy Rating	MT
23-03-14	Wedbush Adjusts Price Target on Cogent Biosciences to $20 From $19, Maintains Outperform Rating	MT
23-01-05	SVB Securities Adjusts Price Target on Cogent Biosciences to $20 From $18, Maintains Outperform Rating	MT
22-12-14	Needham Starts Cogent Biosciences With Buy Rating, Price Target is $24	MT
22-12-13	Guggenheim Adjusts Price Target on Cogent Biosciences to $24 From $22, Maintains Buy Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	COGENT BIOSCIENCES, INC.					+39.35%
	WUXI APPTEC CO., LTD.					+17.16%
	ARGENX SE					+20.43%
	BIONTECH SE					+34.66%
	INSMED INCORPORATED					+98.97%
	WUXI BIOLOGICS (CAYMAN) INC.					+21.54%
	GENMAB A/S					+28.71%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+17.22%
	PHARMAESSENTIA CORPORATION					+1.26%
	EXELIXIS, INC.					-1.47%
	Average					+27.78%
	Weighted average by Cap.					+26.73%